Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

References

• World Health Organization Diabetes Fact Sheet Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html Accessed Dec 29, 2009
   Google Scholar
• Centers for Disease Control and Prevention National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007 Atlanta, GA US Department of Health and Human Services, Centers for Disease Control and Prevention 2008
   Google Scholar
• Ong KL Cheung BM Wong LY Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004 Ann Epidemiol 2008 18 222 229 18201902
   PubMed Web of Science ®Google Scholar
• Resnick HE Foster GL Bardsley J Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: The National Health and Nutrition Examination Survey Diabetes Care 2006 29 531 537 16505501
   PubMed Web of Science ®Google Scholar
• Turner RC Cull CA Frighi V UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 1 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA 1999 281 2005 2012 10359389
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA 10-year follow-up of intensive glucose control in type 1 diabetes N Engl J Med 2008 359 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type I diabetes: A progressive disease Diabetes 1995 44 1249 1258 7589820
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 1 diabetes mellitus: An algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 1 diabetes: A consensus algorithm for the initiation and adjustment of therapy Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Byetta^® (Package insert) San Diego, CA Amylin Pharmaceuticals, Inc 2009
   Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Farilla L Bulotta A Hirshberg B Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 2003 144 5149 5158 12960095
   PubMed Web of Science ®Google Scholar
• Victoza^® (Package insert) Princeton, NJ Novo Nordisk Inc 2010
   Google Scholar
• Elrick H Stimmler L Hlad CJ Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 1964 24 1076 1082 14228531
   PubMed Web of Science ®Google Scholar
• Drucker DJ Enhancing incretin action for the treatment of type 1 diabetes Diabetes Care 2003 26 2929 2940 14514604
   PubMed Web of Science ®Google Scholar
• Nauck MA Homberger E Siegel EG Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 1986 63 492 498 3522621
   PubMed Web of Science ®Google Scholar
• Nauck M Stockmann F Ebert R Reduced incretin effect in type 1 (non-insulin-dependent) diabetes Diabetologia 1986 29 46 52 3514343
   PubMed Web of Science ®Google Scholar
• Orskov C Wettergren A Holst JJ Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day Scand J Gastroenterol 1996 31 665 670 8819215
   PubMed Web of Science ®Google Scholar
• McKennon SA Campbell RK The physiology of incretin hormones and the basis for DPP-4 inhibitors Diabetes Educ 2007 33 55 66 17272793
   PubMed Web of Science ®Google Scholar
• Vilsboll T Holst JJ Incretins, insulin secretion and type 1 diabetes mellitus Diabetologia 2004 47 357 366 14968296
   PubMed Web of Science ®Google Scholar
• Vilsboll T Krarup T Deacon CF Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 1 diabetic patients Diabetes 2001 50 609 613 11246881
   PubMed Web of Science ®Google Scholar
• Rachman J Barrow BA Levy JC Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 1997 40 205 211 9049482
   PubMed Web of Science ®Google Scholar
• Kjems LL Holst JJ Volund A The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 1 and nondiabetic subjects Diabetes 2003 52 380 386 12540611
   PubMed Web of Science ®Google Scholar
• Hojberg PV Zander M Vilsboll T Near normalization of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 1 diabetes Diabetologia 2008 51 63 40
   Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 1 diabetes mellitus J Clin Ivest 1993 91 301 307
   PubMed Web of Science ®Google Scholar
• Orskov C Holst JJ Nielsen OV Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach Endocrinology 1988 123 2009 2013 2901341
   PubMed Web of Science ®Google Scholar
• Willms B Werner J Holst JJ Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 1 (noninsulin-dependent) diabetic patients J Clin Endocrinol Metab 1996 81 327 332 8550773
   PubMed Web of Science ®Google Scholar
• Nauck MA Niedereichholz U Ettler R Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273 E981 E988 9374685
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Astrup A Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Deacon CF Nauck MA Toft-Nielsen M Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type I diabetic patients and in healthy subjects Diabetes 1995 44 1126 1131 7657039
   PubMed Web of Science ®Google Scholar
• Knudsen LB Nielsen PF Huusfeldt PO Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 2000 43 1664 1669 10794683
   PubMed Web of Science ®Google Scholar
• Gonzalez C Beruto V Keller G Investigational treatments for type 1 diabetes mellitus: Exenatide and liraglutide Expert Opin Investig Drugs 2006 15 887 895
   PubMed Web of Science ®Google Scholar
• Steensgaard D Thomsen J Olsen H The molecular basis for the delayed absorption of the once-daily human GLP-1 analog, liraglutide Diabetes 2008 57 A164
   Web of Science ®Google Scholar
• Agerso H Jensen L Elbrond B The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002 45 195 202 11935150
   PubMed Web of Science ®Google Scholar
• Elbrond B Jakobsen G Larsen S Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide-1 derivative, in healthy male subjects Diabetes Care 2002 25 1398 1404 12145241
   PubMed Web of Science ®Google Scholar
• Juhl C Hollingdal M Sturis J Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 1 diabetes Diabetes 2002 51 424 429 11812750
   PubMed Web of Science ®Google Scholar
• Degn K Juhl C Sturis J One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 1 diabetes Diabetes 2004 53 5 1187 1194 15111485
   PubMed Web of Science ®Google Scholar
• Jacobsen L Hindsberger C Robson R Effect of renal impairment on the pharmacokinetics of the GLP-1 analog liraglutide Br J Clin Pharmacol 2009 68 6 898 905 20002084
   PubMed Web of Science ®Google Scholar
• McGill J Insights from the Liraglutide Clinical Development Program – the Liraglutide Effect and Action in Diabetes (LEAD) studies Postgrad Med 2009 121 3 16 25 19491536
   PubMed Web of Science ®Google Scholar
• Flint A Nazzal K Jagielski P Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analog liraglutide Diabetes 2007 56 A145
   Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G for the LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 1 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brandle M for the LEAD-1 SU Study Group Liraglutide, a once-daily human GLP-1 analog, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 1 diabetes (LEAD-1 SU) Diabet Med 2009 26 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K for LEAD-2 Metformin Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 1 diabetes mellitus (LEAD-2 Met) Diabetes Care 2009 32 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R for the LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 1 diabetes (LEAD-3 Mono): A randomized, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB for the LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 1 diabetes mellitus (LEAD-4 Met + TZD) Diabetes Care 2009 52 2046 2055
   Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 1 diabetes mellitus: A randomized controlled trial (LEAD-5 met + SU) Diabetologia 2009 52 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Chang AM Jakobsen G Sturis J The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 1 diabetic patients after a single dose Diabetes 2003 52 1786 1791 12829647
   PubMed Web of Science ®Google Scholar
• Madsbad S Schmitz O Ranstam J Jakobsen G Matthews DR Improved glycemic control with no weight increase in patients with type 1 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care 2004 27 1335 1342 15161785
   PubMed Web of Science ®Google Scholar
• Vilsboll T Zdravkovic M Le-Thi T Liraglutide, a long- acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 1 diabetes Diabetes Care 2007 30 6 1608 1610 17372153
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analog Mol Cell Endocrinol 2009 297 137 140 19041364
   PubMed Web of Science ®Google Scholar
• Parks M Rosebraugh C Weighing risks and benefits of liraglutide – The FDA’s review of a new antidiabetic therapy N Engl J Med 362 9 774 777 20164475
   PubMed Web of Science ®Google Scholar
• NovoNordisk Liraglutide (Victoza^®) Press Release Available from URL: http://www.novonordisk.com/include/asp/exe_news_attachment.pdf?sAttachmentGUID=62e55769-34f2-4022-b820-7ca1cd5bffaf Accessed Jan 6, 2010
   Google Scholar
• European Medicines Agency Liraglutide (Victoza^®): Summary of Product Characteristics Available from URL: http://www.ema.europa.eu/human-docs/PDFs/EPAR/victoza/H-1026-PI-en.pdf Accessed Jan 6, 2010
   Google Scholar
• Nauck MA Hompesch M Filipczak R Five weeks of treatment with the GLP-1 analog liraglutide improves glycaemic control and lowers body weight in subjects with type 1 diabetes Exp Clin Endocrinol Diabetes 2006 114 417 423 17039422
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes: 2009 Diabetes Care 2009 32 Suppl 1 S13 S61 19118286
   PubMed Web of Science ®Google Scholar
• Jendle J Nauck MA Matthews DR Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analog for type 1 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue Diabetes Obes Metab 2009 11 1163 1172 19930006
   PubMed Web of Science ®Google Scholar
• Astrup A Rossner S Van Gaal L Effects of liraglutide in the treatment of obesity: A randomized, double-blind, placebo-controlled study Lancet 2009 374 1606 1616 19853906
   PubMed Web of Science ®Google Scholar